Insights+

Insights+: The US FDA New Drug Approvals in October 2021

Insights+: The US FDA New Drug Approvals in October 2021

The US FDA has approved 4 NDAs and 2 BLAs in 2021, leading to treatments for patients and advan...

Insights+ Key Biosimilars Events of October 2021

Insights+ Key Biosimilars Events of October 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+: The US FDA New Drug Approvals in September 2021

Insights+: The US FDA New Drug Approvals in September 2021

The US FDA has approved 5 NDAs and 2 BLAs in 2021, leading to treatments for patients and advan...

Insights+ Key Biosimilars Events of September 2021

Insights+ Key Biosimilars Events of September 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Insights+: The US FDA New Drug Approvals in August 2021

Insights+: The US FDA New Drug Approvals in August 2021

The US FDA has approved 3 BLAs and 2 NDAs in 2021, leading to treatments for patients and advan...

Insights+ Key Biosimilars Events of August 2021

Insights+ Key Biosimilars Events of August 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safet...

Image